Document |
Document Title |
JP2005519874A |
The present invention relates to the treatment of Alzheimer's disease and other similar diseases, and more specifically to the use of compounds that inhibit beta-secretase, an enzyme that cleaves amyloid precursor protein to produce A be...
|
JP2005518338A |
The present invention is directed to the separation of enantiomers of racemates of formula (I). The separation proceeds by applying deemed racemates to continuos enantioselective chromatography like SMB. The methods predominantly is perf...
|
JPWO2003068753A1 |
For stress, which contains a compound represented by the general formula (I) (the symbol in the formula is as described in the specification), a mitochondrial benzodiazepine receptor (MBR) antagonist composed of the compound, and the com...
|
JP2005511478A |
Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain.
|
JP2005104990A |
To obtain a new agonist of a peptide hormone, vasopressin.A compound represented by formulae 1 or formula 2 is provided. The compound has antidiuretic action and is useful for treating polyuria, incontinentia urinae, and the like.
|
JP2005089298A |
To provide a new naphthalene compound exhibiting HIV-inhibiting activities and its pharmaceutical use, more specifically an HIV-inhibiting agent comprising a compound having a naphthalene structure, its pharmaceutically acceptable salts,...
|
JP2005070055A |
To provide a means effective for treating a female accompanied with a female sexual dysfunction (FSD), in particular, female sexual arousal dysfunction (FSAD).This assay method for identifying a medicine used for the treatment of the FSA...
|
JP2005068138A |
To provide a compound having hypolipemic action, such as squalene synthase inhibitory action (cholesterol decreasing action) and triglyceride decreasing action, safer and stronger than ever, and useful as a medicament of a prophylactic, ...
|
JP3630449B2 |
PURPOSE: To obtain a novel tricyclic compound which has antagonist activity at V1 and/or V2 receptors and exhibits in vivo vasopressin antagonist activity and is useful for treatment of diseases characterized by excess renal reabsorption...
|
JP2005043377A |
To provide medicine that can be used for treating a female with FSD, especially FSAD, and to provide an assay method of the medicine or the like.The method is the assay method for identifying the medicine that can be used for treating fe...
|
JP2005503993A |
The invention provides compositions and methods for altering insulin secretion using an agent that inhibits calcium efflux via the mitochondrial calcium/sodium antiporter (MCA). Methods of treatment are thereby provided, and are particul...
|
JP2005021167A |
To provide an effective method for treating a female suffering from female sexual dysfunction (FSD), in particular, female sexual arousal dysfunction (FSAD).A method for assaying an agent capable of potentiating cAMP in the sexual genita...
|
JP2005013237A |
To provide an effective method for treating a female suffering from female sexual dysfunction (FSD), in particular, female sexual arousal dysfunction (FSAD).The method comprises assaying an agent capable of potentiating cAMP in the genit...
|
JP2004346059A |
To provide a TGR5 (G protein-coupled receptor) receptor agonist useful for treating various diseases.This TGR5 receptor agonist contains a fused ring compound expressed by formula (1) (wherein ring A is an aromatic ring which may be subs...
|
JP2004331659A |
To provide a new pharmaceutical having RFRP receptor function regulating action.This RFRP receptor function regulating agent contains a compound expressed by formula (I) [ring A is an aromatic ring which may be substituted; ring B is a b...
|
JP2004315500A |
To obtain a new medicine useful as a skeletal muscle protective agent.This skeletal muscle protective agent contains a compound having squalene synthase inhibitory activity, or its salt or its prodrug.
|
JP2004534057A |
The present invention provides prodrugs of GABA analogs, pharmaceutical compositions of prodrugs of GABA analogs and methods for making prodrugs of GABA analogs. The present invention also provides methods for using prodrugs of GABA anal...
|
JP3585552B2 |
PURPOSE: To keep the lower impressed voltage on an electrode in regeneration of a nicotinamide co-enzyme by incorporating compds., such as substd. or unsubstd. 9H-acridin-2-ones, having a mediation function on an electrode surface. CONST...
|
JPWO2002096891A1 |
Provided are a dihydrodialyloxazepine derivative represented by the following formula [1] or an analog thereof, and a pharmaceutical composition containing these. These compounds show excellent functional gastrointestinal disease improvi...
|
JP3563738B2 |
An amino acid derivative having an angiotensin I-converting enzyme inhibitor activity, a vasopressin antagonism and an atrial natriuretic peptide hydrolase inhibitor activity, and represented by general formula (I) wherein R<1> represent...
|
JP2004517085A |
The present invention relates to compounds of the formula Iwherein R1, R2, R3, X, Y and the dashed line are as defined in the specification, to intermediates for their preparation, to pharmaceutical compositions containing them and to th...
|
JP2004512318A |
A C-nitroso compound having a molecular weight ranging from about 225 to about 1,000 (from about 225 to about 600 for oral administration) on a monomeric basis wherein a nitroso group is attached to a tertiary carbon, which is obtained b...
|
JP2004509954A5 |
|
JP2004509954A |
Compounds having the general formula wherein R1a, R1b, R1c, X1, X2, R2, R3, R4, R5, R6, n, Y and Z are as defined in the specification, methods of using such compounds for the treatment of diseases and pharmaceutical composition comprisi...
|
JP2004509103A |
One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine, ser...
|
JP3497164B2 |
PCT No. PCT/US92/05463 Sec. 371 Date Jun. 26, 1992 Sec. 102(e) Date Jun. 26, 1992 PCT Filed Jun. 26, 1992 PCT Pub. No. WO93/00095 PCT Pub. Date Jan. 7, 1993This invention relates to compounds of the formula: wherein A1 to A5 form an acce...
|
JP3487611B2 |
PURPOSE: To obtain new compds. useful as dual inhibitors having inhibitory activity against angiotensin converting enzyme and neutral endopeptidase in the treatment of hypertension, congestive heart failure, hepatocirrhosis, etc. CONSTIT...
|
JP3479796B2 |
To obtain a compound having squalene synthase inhibitory action, hypocholesterolemic action, triglyceride-depressive action, thus useful for preventing and treating hyperlipemia and arteriosclerosis, etc. This compound (salt) is expresse...
|
JP2003534230A |
[Chemical 1]
|
JP2003321461A |
To obtain a new fused biphenyl derivative having tachykinin receptor antagonism, especially NK1 receptor antagonism.The fused biphenyl derivative is expressed by general formula (1) (wherein A ring and B ring express each a benzene ring ...
|
JP3462234B2 |
PURPOSE: To obtain a new heterocyclic compound, having excellent choline esterase inhibiting activity and antidepressant action and useful as a therapeutic or a preventing agent for senile dementia. CONSTITUTION: The compound of formula ...
|
JP2003531824A |
Novel derivatives of prostaglandin compounds of the F-series (PGF), specifically macrocyclic internal 1,15-lactones of fluprostenol and related PGF analogs, such as cloprostenol or latanoprost. The novel analogs can be formulated into op...
|
JP2003300962A |
To provide a benzodiazepinedione derivative acting as a non-peptide platelet aggregation inhibitor.This benzodiazepinedione derivative is provided for a therapeutic composition which strongly inhibits the bonding of fibrinogen to GPIIbII...
|
JP2003530388A |
A compound having the general formula (I) and methods of using such compounds for the treatment of diseases and pharmaceutical composition comprising such compounds.
|
JP3446052B2 |
|
JP2003261450A |
To obtain an antimycotic agent that contains a zofimarin derivative bearing an oxazepane ring, or a pharmacologically acceptable ester or salt thereof as an active ingredient.The antimycotic agent contains the zofimarin derivative repres...
|
JP2003176268A |
To provide an enamine compound which is an organic photoconductive material usable for electrophotographic photoreceptor, etc., with a high charging potential, high sensitivity, and manifesting sufficient optical response in a low- tempe...
|
JP2003119137A |
To provide a compound and its pharmaceutically permissible salt effective for suppressing the HIV proliferation of affected cell of latency phase and enabling the suppression of the proliferation of virus in the latency phase from the in...
|
JP2003081873A |
To provide a new medicine that is useful as a prophylactic or therapeutic for organ functional disorder, organ insufficiency, obesity and their deuteropathy and a new medicine having the ubiquinone-increasing action.The prophylactic or t...
|
JP2003064063A |
To provide a compound which has lowering activity of cholesterol and triglyceride-reducing activity and is useful for preventing or treating hyperlipemia.The compound represented by formula [I] [R1 is 3- carboxypropyl, 1-carboxyethyl, or...
|
JP2003500392A |
One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various cellular receptors, including opiate rece...
|
JP2002537260A |
The present invention relates to dibenzo-azepine derivatives and their use as alphaV integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors alphaVbeta3, alphaVbe...
|
JP2002241368A |
To provide an excellent neuropeptide Y(NPY) antagonist, i.e., an antifeeding agent, a therapeutic agent for myocardial infarction, a therapeutic agent for angina pectoris and an antihypertensive agent.A compound represented by the formul...
|
JP2002234879A |
To provide a method for producing an amide compound in high efficiency by a Beckmann rearrangement of an oxime compound in a liquid phase under a mild reaction condition.This method for producing an amide compound such as - caprolactam f...
|
JP2002518451A |
Disclosed are compounds which inhibit beta -amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits...
|
JP2002518481A |
Compounds of formula (I), wherein W is a cyclic group of the type (2); (3); Y is represented by the formula (II); these compounds inhibit beta -amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzh...
|
JP2002517488A |
The present invention is directed to a process for the preparation of a compound of formula (X-a):or a pharmaceutically acceptable salt form thereof, wherein:R1 is selected from the group consisting of:C1-5 alkyl substituted with 0-5 R1a...
|
JP2002161086A |
To provide a zofimarin derivative useful as a medicament (especially, an antimycotic agent), and a pharmacologically acceptable ester or salt thereof.This new compound is a zofimarin drivative of the general formula (I) (wherein, R1 is f...
|
JP3286056B2 |
PURPOSE: To obtain a tricyclic condensed heterocyclic derivative, having excellent inhibiting activities against choline esterases and inhibiting actions on uptake of monoamines and useful as a therapeutic and preventing agent for senile...
|
JP3283628B2 |
PURPOSE: To obtain a new compound having action to inhibit a squalene synthetic enzyme and antifungal action and useful in treatment for hypercholesterolemia, coronary arteriosclerotic disease, infection of fungi, etc. CONSTITUTION: A co...
|